Led by North India's most experienced BMT specialist with 2,500+ transplants, Fortis FMRI Gurugram is one of the region's largest bone marrow transplant centres treating leukaemia, thalassaemia, and aplastic anaemia.
Looking for a specific insurance provider? Simply use our search function or contact us for assistance and our knowledgeable team will happily verify whether your provider is accepted at our facility.
Ask about your insurance
No. Fortis offers transplant options for patients without a fully matched donor.
If you do not have a matched sibling, Fortis can access international bone marrow registries to search for a matched unrelated donor (MUD). If no registry match is found, a haploidentical transplant using a parent, child, or sibling as a half-matched donor is available.
Fortis Gurugram is one of the few centres in India performing MUD transplants specifically for thalassaemia. Your donor situation is assessed as part of the pre-travel case review so you know your options before you arrive.
International BMT patient support at Fortis is available 24/7 through My 1Health.
The team manages your visa documentation, airport transfer, and post-discharge telemedicine follow-up. No travel commitment is needed to get started.
Most BMT patients stay between 6 and 12 weeks in India, depending on transplant type and recovery progress.
General stay expectations:
A detailed treatment and stay itinerary is prepared for you and your family before you travel.
BMT costs at Fortis depend on the transplant type, donor availability, conditioning protocol, length of hospital stay, and your clinical complexity. A personalised written estimate is provided before you travel.
Cost benchmarks at Fortis India:
Complications such as graft-versus-host disease and extended hospital stays can affect the final cost, which is why a detailed estimate based on your specific case is provided before you book any flights.
Haploidentical transplants achieve 65% three-year survival in paediatric patients and 55% in adults for AML and ALL. For paediatric AML specifically, a retrospective study of 48 patients at Fortis showed GVHD-free relapse-free survival (GRFS) of 58%.
For autologous transplants, Indian studies show 95% successful engraftment in the immediate post-transplant period.
Dr. Rahul Bhargava has completed 2,500+ transplants at FMRI Gurugram, with outcomes that are consistently cited as among the strongest in North India.
Success rates vary by diagnosis, transplant type, and disease stage at the time of transplant, which is why a case-specific clinical assessment is completed before your treatment begins.
Three things set Fortis apart specifically for international BMT patients: